Schizophrenia Management

Definition and Diagnosis

Treatment-resistant schizophrenia (TRS) is defined as the failure to respond adequately to at least two different antipsychotic trials in adequate doses and durations, with persistence of significant symptoms despite this treatment, as per the American Psychiatric Association 1
A confirmed diagnosis of schizophrenia requires failure of therapeutic response in at least two adequate trials with different antipsychotics, each lasting a minimum of 6 weeks and with a dose equivalent to at least 600mg/day of chlorpromazine, with assessment of significant symptoms using standardized scales such as PANSS or BPRS 1

The assessment of treatment resistance should specify which domains of symptoms are resistant, including positive, negative, cognitive, or combinations of domains, and should include prospective evaluation with at least one trial with a long-acting injectable antipsychotic (LAI) to rule out non-adherence as a cause of resistance, with a minimum duration of 4 months for the LAI 1
The temporal development of resistance should be characterized as early (within the first year of treatment), medium (1-5 years after treatment initiation), or late (more than 5 years after treatment initiation) 1

Clozapine is the gold standard for treatment-resistant schizophrenia, and should be considered after failure of at least two adequate antipsychotic trials, as recommended by the American Psychiatric Association 1
Long-acting injectable (LAI) formulations should be considered in cases of suspected non-adherence before labeling a case as treatment-resistant, as recommended by the American Psychiatric Association 1 and the British Journal of Psychiatry 2
For first-episode psychosis, an SGA should be started due to lower EPS risk, considering metabolic risk factors in medication selection, and for patients with high metabolic risk, consider aripiprazole, ziprasidone, or high-potency FGA with careful EPS monitoring, avoiding clozapine and olanzapine as first-line options, as recommended by the American Psychiatric Association 1
Antipsychotic trials should last at least 6 weeks at therapeutic doses before determining efficacy, and consideration of LAI formulations is recommended when adherence is a concern, to avoid unnecessary medication changes, as recommended by the American Psychiatric Association 1 and the British Journal of Psychiatry 2